0001628280-20-013454.txt : 20200910
0001628280-20-013454.hdr.sgml : 20200910
20200910172438
ACCESSION NUMBER: 0001628280-20-013454
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200908
FILED AS OF DATE: 20200910
DATE AS OF CHANGE: 20200910
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CLARK IAN T
CENTRAL INDEX KEY: 0001336504
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38683
FILM NUMBER: 201169343
MAIL ADDRESS:
STREET 1: SOLAZYME, INC.
STREET 2: 225 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Guardant Health, Inc.
CENTRAL INDEX KEY: 0001576280
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 454139254
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 PENOBSCOT DR.
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 855-698-8887
MAIL ADDRESS:
STREET 1: 505 PENOBSCOT DR.
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
wf-form4_159977306538883.xml
FORM 4
X0306
4
2020-09-08
0
0001576280
Guardant Health, Inc.
GH
0001336504
CLARK IAN T
505 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
1
0
0
0
COMMON STOCK
2020-09-08
4
M
0
9146
4.18
A
13789
D
COMMON STOCK
2020-09-08
4
S
0
5263
88.6912
D
8526
D
COMMON STOCK
2020-09-08
4
S
0
2747
89.7751
D
5779
D
COMMON STOCK
2020-09-08
4
S
0
1136
90.5394
D
4643
D
STOCK OPTION (RIGHT TO BUY)
4.18
2020-09-08
4
M
0
8070
0
D
2027-05-30
COMMON STOCK
8070.0
10760
D
STOCK OPTION (RIGHT TO BUY)
4.18
2020-09-08
4
M
0
1076
0
D
2027-11-29
COMMON STOCK
1076.0
7532
D
These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $88.18 to $89.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $89.185 to $90.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $90.22 to $90.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017.
The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017.
/s/ John Saia, as attorney-in-fact for Ian T. Clark
2020-09-10